Literature DB >> 31612306

Total pleural coverage followed by lung transplantation in patient with lymphangioleiomyomatosis.

Do Hyung Kim1, Hyo Yeong Ahn2, Bong Soo Son1, Joohyung Son1.   

Abstract

Tuberous sclerosis complex lymphangioleiomyomatosis (TSC-LAM) is a rare disease, which may develop an intractable pneumothorax. Chemical or mechanical pleurodesis is a general management to prevent recurrence of pneumothorax, rendering it difficult to later dissect the pleura and control intraoperative bleeding. Since total pleural coverage (TPC) alternative to pleurodesis has been firstly reported by Kurihara et al. (Jpn J Thorac Cardiovasc Surg 54:274, 2006), TPC was performed in case of a 46-year-old female with a secondary spontaneous pneumothorax caused by TSC-LAM and followed by lung transplantation. Final pathological report showed the reinforced visceral pleura in the absence of dense adhesions.

Entities:  

Keywords:  Lung transplantation; Lymphangioleiomyomatosis; Pneumothorax

Mesh:

Year:  2019        PMID: 31612306      PMCID: PMC7522064          DOI: 10.1007/s11748-019-01217-0

Source DB:  PubMed          Journal:  Gen Thorac Cardiovasc Surg        ISSN: 1863-6705


Introduction

Tuberous sclerosis complex lymphangioleiomyomatosis (TSC-LAM) is a rare disease, which may trigger an intractable pneumothorax. Chemical or mechanical pleurodesis is recommended to prevent recurrence, rendering it difficult to later dissect the pleura and control intraoperative bleeding. We performed total pleural coverage (TPC) as an alternative to pleurodesis, based on the recommendations of recent reports. Pathological findings are important when evaluating the efficacy of TPC. Herein, we report the case of a 46-year-old female with a secondary spontaneous pneumothorax caused by TSC-LAM who underwent TPC prior to lung transplantation.

Case report

A 46-year-old female was admitted to the emergency room with dyspnea, and right pneumothorax was diagnosed. Chest computed tomography (CT) revealed the features of lymphangioleiomyomatosis (LAM), including facial angiofibroma, hypomelanotic macules, and renal angiomyolipoma; we thus diagnosed tuberous sclerosis complex (TSC)-LAM. As the air leakage had developed 10 days prior, airleak control was performed by video-assisted thoracoscopic surgery (VATS), which showed multiple lung cysts with ruptured bullae surrounded by a dense adhesion in the right upper lobe. After releasing the adhesion, the bullae was ligated, and covered a huge fragile cyst at risk of imminent rupture with an absorbable polyglycolic acid sheet (Neoveil; Gunze Ltd., Kyoto, Japan) and fibrin sealant (Tisseel; Baxter Healthcare Corp., Deerfield, IL, USA). To prevent recurrence, we performed total pleural coverage (TPC) of the entire lung surface using 12 sheets of oxidized regenerated cellulose (ORC) mesh (Ethicon SURGICEL ® absorbable Hemostat gauze, Johnson & Johnson, Brunswick, NJ, USA) (Fig. 1). The patient was discharged on postoperative day (POD) 9.
Fig. 1

Gross findings of lungs correlated to computed tomographic images. a Ruptured bullae were evident in the right upper lobe, as was a dense adhesion around the bullae. The adhesion was released and the bullae loop ligated. b The ruptured area (asterisk) contained bullae, as revealed by CT. c A huge fragile cyst at risk of immediate rupture was covered by an absorbable polyglycolic acid sheet (e). d The fragile cyst (arrow) was located near the bullae, as revealed by CT. f We performed total pleural coverage (TPC) of the entire lung

Gross findings of lungs correlated to computed tomographic images. a Ruptured bullae were evident in the right upper lobe, as was a dense adhesion around the bullae. The adhesion was released and the bullae loop ligated. b The ruptured area (asterisk) contained bullae, as revealed by CT. c A huge fragile cyst at risk of immediate rupture was covered by an absorbable polyglycolic acid sheet (e). d The fragile cyst (arrow) was located near the bullae, as revealed by CT. f We performed total pleural coverage (TPC) of the entire lung One month later, she was readmitted to treat a contralateral recurrent pneumothorax. She again underwent TPC after ligation of the ruptured bullae and was discharged on POD 22. Home oxygen therapy and sirolimus 1 mg daily was prescribed, because the dyspnea remained aggravated even after operation. Fourteen months later, lung transplantation was successfully performed; both lungs that had been subjected to TPC were sampled, revealing thickened visceral pleura surrounded by minimal inflammation (Fig. 2). After the operation, oxygen therapy was no longer necessary and she was discharged on POD 41 without any complication.
Fig. 2

Gross and microscopic findings of lungs that had undergone TPC. a, b The surfaces of both the right (a) and left (b) lungs were relatively smooth. c, d The visceral pleura that had undergone TPC were thickened, and minimal adhesion of the visceral to the parietal pleura was evident. e Elastica-Masson stain showed the thickened visceral pleura above the natural visceral pleura (arrow)

Gross and microscopic findings of lungs that had undergone TPC. a, b The surfaces of both the right (a) and left (b) lungs were relatively smooth. c, d The visceral pleura that had undergone TPC were thickened, and minimal adhesion of the visceral to the parietal pleura was evident. e Elastica-Masson stain showed the thickened visceral pleura above the natural visceral pleura (arrow)

Discussion

Tuberous sclerosis complex (TSC) is an autosomal-dominant genetic disorder affecting multiple organs. LAM is one manifestation of TSC, caused by a TSC2 mutation triggering aberrant cell proliferation [2]. Since recurrent pneumothorax is one of the most common complications seen in LAM patients, chemical or mechanical pleurodesis has been recommended to prevent recurrence [3, 4]. However, after pleurodesis, it was difficult to dissect the pleura and control intraoperative bleeding, because of severe adhesion. Therefore, TPC was recommended as an alternative to pleurodesis, in which ORC was used to cover the entire pleura to make thickened visceral pleura, as in studies of Noda et al., Kurihara et al., Kusu et al. [3, 5–7]. Although sirolimus inhibits tissue proliferation and the release of lymphangiogenic growth factors [8, 9], and relieves symptoms, the dyspnea worsened in our case as disease progressed, and lung transplantation was performed at 15 months after the initial operation. The pathology showed the thickened pleura without severe inflammation (Fig. 2). Although animal experiments have been performed to check adhesion or visceral pleural thickness after pleurodesis [3], no report on a patient treated via TPC who later underwent lung transplantation has appeared. As shown here, TPC might be one of the good tools for prevention of recurred pneumothorax, making the thickened visceral pleura useful to describe our patient with LAM who underwent TPC followed by lung transplantation; examination of the extracted lung showed that our treatment reinforced the visceral pleura in the absence of dense adhesions.

Conclusion

TSC-LAM is a rare disease, which may trigger an intractable pneumothorax. TPC might be one of the good tools for prevention of recurred pneumothorax, making the thickened visceral pleura useful to describe our patient with LAM who underwent TPC followed by lung transplantation.
  8 in total

Review 1.  Latest treatments for spontaneous pneumothorax.

Authors:  Masatoshi Kurihara; Hideyuki Kataoka; Aki Ishikawa; Reina Endo
Journal:  Gen Thorac Cardiovasc Surg       Date:  2010-03-11

Review 2.  Tuberous sclerosis complex: Recent advances in manifestations and therapy.

Authors:  Mari Wataya-Kaneda; Motohide Uemura; Kazutoshi Fujita; Haruhiko Hirata; Keigo Osuga; Kuriko Kagitani-Shimono; Norio Nonomura
Journal:  Int J Urol       Date:  2017-07-01       Impact factor: 3.369

3.  Rapamycin for lymphangioleiomyomatosis: optimal timing and optimal dosage.

Authors:  Kai-Feng Xu; Xinlun Tian; Yanli Yang; Hongbing Zhang
Journal:  Thorax       Date:  2018-02-02       Impact factor: 9.139

4.  A total pleural covering technique in patients with intractable bilateral secondary spontaneous pneumothorax: Report of five cases.

Authors:  Masafumi Noda; Yoshinori Okada; Sumiko Maeda; Tetsu Sado; Akira Sakurada; Yasushi Hoshikawa; Chiaki Endo; Takashi Kondo
Journal:  Surg Today       Date:  2011-09-16       Impact factor: 2.549

5.  An experience with the modified total pleural covering technique in a patient with bilateral intractable pneumothorax secondary to lymphangioleiomyomatosis.

Authors:  Masafumi Noda; Yoshinori Okada; Sumiko Maeda; Tetsu Sado; Akira Sakurada; Yasushi Hoshikawa; Chiaki Endo; Takashi Kondo
Journal:  Ann Thorac Cardiovasc Surg       Date:  2010-12       Impact factor: 1.520

6.  Null allele alpha-1 antitrypsin deficiency: case report of the total pleural covering technique for disease-associated pneumothorax.

Authors:  Takashi Kusu; Tomoyuki Nakagiri; Masato Minami; Yasushi Shintani; Yoshihisa Kadota; Masayoshi Inoue; Noriyoshi Sawabata; Meinoshin Okumura
Journal:  Gen Thorac Cardiovasc Surg       Date:  2012-04-28

7.  A Total Pleural Covering for Lymphangioleiomyomatosis Prevents Pneumothorax Recurrence.

Authors:  Masatoshi Kurihara; Teruaki Mizobuchi; Hideyuki Kataoka; Teruhiko Sato; Toshio Kumasaka; Hiroki Ebana; Sumitaka Yamanaka; Reina Endo; Sumika Miyahashira; Noriko Shinya; Kuniaki Seyama
Journal:  PLoS One       Date:  2016-09-22       Impact factor: 3.240

8.  Efficacy of sirolimus for the prevention of recurrent pneumothorax in patients with lymphangioleiomyomatosis: a case series.

Authors:  Li Zhou; Ruoyun Ouyang; Hong Luo; Siying Ren; Ping Chen; Yating Peng; Ting Liu; Guiqian Liu
Journal:  Orphanet J Rare Dis       Date:  2018-09-21       Impact factor: 4.123

  8 in total
  1 in total

1.  The effects of total pleural covering on pneumothorax recurrence and pulmonary function in lymphangioleiomyomatosis patients without history of pleurodesis or thoracic surgeries for pneumothorax.

Authors:  Emily Suzuki; Masatoshi Kurihara; Kenji Tsuboshima; Kenichi Watanabe; Shouichi Okamoto; Kuniaki Seyama
Journal:  J Thorac Dis       Date:  2021-01       Impact factor: 2.895

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.